Table 2.
Patient baseline characteristics of clinical studies included in this meta-analysis.
| Publication | Number | Age (yr), mean (SD) | PV (ml), mean (SD) | IPSS, mean (SD) | Qol, mean (SD) | BPHII, mean (SD) | Qmax (ml/s), mean (SD) | PVR (ml), mean (SD) | SHIM, mean (SD) | MSHQ-EjD, mean (SD) | MSHQ-Bother, mean (SD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Roehrborn (2013) [20] | 140 | 67 (8.6) | 44.5 (12.4) | 22.2 (5.4) | 4.6 (1.1) | 6.9 (2.8) | 8.9 (2.2) | 85.5 (69.2) | 13.0 (8.4) | 8.7 (3.2) | 2.4 (1.7) |
| Roehrborn (2015) [21] | |||||||||||
| Roehrborn (2015) [22] | |||||||||||
| Roehrborn (2017) [23] | |||||||||||
| McVary (2014) [24] | |||||||||||
| Rukstalis (2016) [26] | 53 | 64 (8.0) | 40.3 (9.9) | 23.3 (5.5) | 4.5 (1.2) | 6.3 (3.0) | 8.8 (4.2) | 67.8 (66.4) | 12.8 (8.3) | 9.5 (10.0) | 2.7 (1.7) |
| Cantwell (2014) [27] | |||||||||||
| Rukstalis (2019) [25] | 45 | 64 (7.0) | 44.2 (11.2) | 24.2 (4.9) | 4.9 (0.8) | 7.7 (2.8) | 7.2 (2.9) | 107.3 (79.9) | 15.1 (9.0) | 9.4 (3.1) | 1.6 (1.8) |
| Shore (2014) [28] | 51 | 66 (7.6) | 41.3 (11.6) | 21.5 (5.4) | 4.6 (1.0) | 6.7 (3.1) | 8.2 (2.2) | 77.1 (74.9) | 16.5 (7.3) | 10.0 (2.6) | 1.8 (1.4) |
| McNicholas (2013) [13] | 102 | 68 (10.0) | 48 (21) | 23.2 (6.1) | 4.7 (1.0) | NA | 8.7 (4.0) | NA | NA | NA | NA |
| Woo (2012) [29] | 64 | 67 (7.3) | 51 (23) | 22.6 (5.4) | 4.9 (0.9) | 7.2 (2.9) | 8.3 (2.2) | 89 (86) | 18.2 (4.9) | 10.6 (2.1) | 1.5 (1.4) |
| Chin (2012) [14] | |||||||||||
| Woo (2011) [30] | |||||||||||
| Bardoli (2017) [31] | 11 | 70.5 (10.2) | 45.5 (15.1) | 25.6 (5.3) | 5.0 (0.6) | NA | 7.0 (2.8) | 306.3 (120.6) | NA | NA | NA |
| Kim (2019) [32] | 32 | 67 (7) | 50 (7) | 19.3 (2.4) | 4.4 (0.6) | NA | 12.1 (2.4) | NA | 18.8 (4.7) | NA | NA |
| Sievert (2019) [33] | 86 | 66.2 (11.5) | 43 (18.8) | 20.82 (6.5) | 4.1 (1.2) | NA | 11.2 (3.2) | 149.5 (251.5) | NA | NA | NA |
| Sonksen (2015) [34] | 44 | 63 (6.8) | 38 (12) | 22 (5.7) | 4.6 (1.1) | 7.3 (2.5) | 9.2 (3.5) | 86 (72) | 20 (4.9) | 11 (2.7) | 1.7 (1.8) |
| Gratzke (2017) [35] | |||||||||||
| Bozkurt (2016) [36] | 17 | 67 (10.8) | 44.1 (14.3) | 22.8 (4.4) | 3.2 (0.9) | NA | 7.6 (2.9) | 50.3 (31.2) | 15.5 (6.3) | 9.7 (2.8) | NA |
BPHII = Benign Prostatic Hyperplasia Impact Index; EjD = ejaculatory dysfunction; IPSS = International Prostate Symptom Score; MSHQ = Male Sexual Health Questionnaire; NA = not available; PV = prostate volume; PVR = postvoid residual volume; Qmax = maximum flow rate; Qol = quality of life; SD = standard deviation; SHIM = Sexual Health Inventory for Men.